🩺 Discovery of a Hidden Key in the Liver that Reduces Harmful Cholesterol
A research team at UT Southwestern Medical Center has identified a protein that acts as a vital key in regulating the amount of harmful cholesterol the liver secretes into the bloodstream. This discovery plays a pivotal role in understanding how to control the molecules that transport fats and cholesterol, which could open new horizons for treating heart disease and fatty liver disease.
The protein in question is known as HELZ2, and it affects the activity of the apolipoprotein B (APOB) gene, which is responsible for producing apoB protein particles that form important particles for transporting cholesterol and fats in the blood.
– HELZ2 affects the stability of mRNA for APOB in liver cells.
– Increasing HELZ2 activity reduces the amount of harmful cholesterol particles in the blood.
– Higher HELZ2 activity causes fat to build up in the liver.
– There is a delicate balance between lowering blood cholesterol and increasing liver fat through HELZ2.
– The discovery opens possible new ways to treat heart disease and fatty liver disease beyond traditional statin medications.
🧬 The Crucial Role of HELZ2 Protein in the Liver
The mechanism of action of HELZ2 protein is based on regulating the stability of the messenger RNA (mRNA) molecule of the APOB gene inside liver cells. This molecule is the genetic message that carries the instructions needed to make apoB protein.
When HELZ2 activity rises, it shortens the life of this message more quickly, so liver cells produce a smaller amount of apoB protein. In turn, this results in fewer lipoprotein particles that transport cholesterol and fats through the blood. This process helps limit the buildup of atherosclerotic plaque, the deposits that clog arteries and increase the risk of heart attacks and strokes.
This control at the mRNA stage is new, as most previous research focused on how the body handles apoB protein after it is formed, while the new study showed HELZ2’s effect before the protein stage, at the “message” level.
HELZ2 adjusts the amount of harmful cholesterol particles in the blood by controlling the lifespan of APOB mRNA inside cells, thereby limiting the number of proteins that form and carry fats.
🧪 Vital Results in Mouse Models
The researchers used genetically modified mouse models carrying a mutation in HELZ2 that increases the activity of this protein. These mice showed surprising results:
- A significant decrease in LDL, the bad cholesterol, and triglycerides in the bloodstream.
- Remarkable protection against atherosclerotic disease that clogs the heart’s arteries.
- Increased fat accumulation inside liver cells.
By contrast, mice without the mutation showed opposite results, indicating that HELZ2 represents a precise “control switch” between the amount of liver fat and cholesterol levels in the blood.
Dr. Zhaohang Zhang, the study’s lead author, said: “We can think of HELZ2 as a control button that manages the amount of cholesterol in the blood versus the amount of fat in the liver. Raising its activity lowers blood cholesterol but increases liver fat, while lowering it produces the opposite.”
These results provide a new understanding of the complex relationship between regulating blood cholesterol and fat accumulation inside the liver, a balance that reflects a challenge in developing treatments for liver and heart diseases.
🧠 A Shift in Dealing with Heart Disease and Fat
Currently, statins are the most common treatment choice for lowering cholesterol and reducing the risks of heart disease. But they focus on the effect after cholesterol particles have been formed in the blood.
The new study highlights that targeting HELZ2 offers a completely different possibility: adjusting the amount of cholesterol at the genetic source by controlling the persistence of the APOB mRNA message inside the liver. This precise step gives us a new mechanism for reducing harmful cholesterol “in advance,” before the proteins that carry it are produced.
This discovery may eventually lead to the development of effective therapeutic approaches for both:
- Atherosclerotic diseases
- Fatty Liver Disease
by gradually manipulating HELZ2 activity to reduce cholesterol in the blood while trying to manage fat accumulation in the liver.
Controlling cholesterol at the level of the mRNA molecule represents a qualitative advance that deepens our understanding of the body’s fat-regulation mechanisms and forms a new foundation for future drug design.
🌱 The Medical Future and Research Opportunities
Scientists see HELZ2 as an “important molecular lever” that can be carefully adjusted to reduce the effects of harmful cholesterol and its impact on the arteries. Its importance lies in the fact that it acts earlier in the pathway of fat-transport particle formation, giving it an advantage in effective control.
Alongside its role in heart disease, HELZ2’s effect on fat accumulation in the liver highlights the importance of studying this protein carefully to understand its potential risks and how to balance them with its benefits. Increased liver fat may lead to separate health complications.
Dr. Bruce Beutler — the Nobel Prize winner in Physiology or Medicine — contributed to developing the large-scale genetic screening system that enabled the discovery of HELZ2’s function. This genetic methodology represents a revolution in medical scientific research, as it enables the discovery of new therapeutic targets through precise detection of the functions of genes and proteins.
Funding and Scientific Support
This research was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases within the National Institutes of Health, confirming the importance and rigor of the scientific work.
🩺 Conclusion
The discovery of HELZ2 protein’s role in controlling harmful cholesterol levels by regulating the stability of the APOB mRNA molecule in the liver opens new horizons for understanding and managing heart disease and fatty liver. While HELZ2 represents a new professional therapeutic opportunity, the challenge remains in finding the optimal balance between reducing harmful cholesterol particles and reducing unwanted fat accumulation in the liver.
This research points to a fundamental shift in cholesterol-lowering strategies, moving from focusing on treating proteins after they are made to controlling the genetic stage before the manufacturing process, thereby providing us with stronger tools to understand and confront complex diseases in the future.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
